On July 20, the European Medicines Agency (EMA) announced the launch of a continuous review of the Covid-19 Vidprevtyn vaccine, developed by the French laboratory Sanofi Pasteur, as Le Figaro reported.
The EMA's decision to initiate ongoing testing is based on preliminary laboratory and clinical findings in adults. This could lead to a possible request for a future vaccine authorization in the European Union.
The results of studies on the vaccine's efficiency should show that the drug triggers a production of antibodies that target Sars-CoV-2, the virus that causes Covid-19, the EMA explained.
The regulator notes that the assessment of a possible license request should taEMAke less time than usual due to the work during the review.
French Industry Minister Agnès Pannier-Runacher said the second phase trial results of the Sanofi Pasteur vaccine are "excellent".
At the moment, the EMA has allowed in the EU four vaccines against coronavirus - Pfizer-BioNTech, Moderna, AstraZeneca and Johnson & Johnson.
As it was reported earlier, in June, the World Health Organization received applications from at least three vaccine manufacturers for emergency approval of additional vaccines against Covid-19.